INS and type 2 diabetes mellitus: The majority of oral hypoglycemic drugs, such as glibenclamide used to manage type 2 diabetes, work by stimulating the secretion of insulin by the pancreatic beta cells, hence leading to a rise in the serum insulin level following administration (Ganesan and Sultan 2018).